Is Eli Lilly's 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

Eli Lilly and Company TodayLLYEli Lilly and Company $632.07 -8.80 (-1.37%) 52-Week Range$ 623.78▼ $972.53Dividend Yield0.95%P/E Ratio51.33Price Target$ 999.50Add to WatchlistFor weight loss drug leaders, the last two weeks have been nothing short of disastrous for shares. Industry pioneer Novo Nordisk A/S NYSE: NVO saw its stock drop nearly 22% on July 29 after lowering its full-year guidance. Then, on Aug. 7, Eli Lilly NYSE: LLY shares fell approximately 14%. The reasoning, however, behind Eli Lilly's decline ...